Want to see ONCY full AI Analyst Report?

Oncolytics Biotech (ONCY) Price & Analysis

1,595 Followers

ONCY Stock Chart & Stats

$1.12

-$0.03(-3.70%)

At close: Jan 08 4:00 PM EST

$1.12

-$0.03(-3.70%)

Day’s Range― - ―

52-Week Range$0.56 - $1.51

Previous CloseN/A

Volume216.96K

Average Volume (3M)1.42M

Market Cap

$113.12M

Enterprise Value$126.85M

Total Cash (Recent Filing)$5.49M

Total Debt (Recent Filing)$508.00K

Price to Earnings (P/E)―

Beta1.29

Next Earnings

Jul 31, 2026

EPS Estimate

-0.05

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.34

Shares Outstanding119,354,065

10 Day Avg. Volume1,526,127

30 Day Avg. Volume1,421,363

Financial Highlights & Ratios

PEG Ratio0.00

Price to Book (P/B)-22.05

Price to Sales (P/S)0.00

P/FCF Ratio-4.17

Enterprise Value/Market Cap1.12

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-3.15K

Enterprise Value/Ebitda-3.83

Forecast

1Y Price Target

$6.00

Price Target Upside435.71% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

EPS Forecast (FY)-0.32

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Intellectual Property ProtectionA granted manufacturing patent extending protection into 2044 secures pelareorep's scalable production know-how, strengthening commercialization readiness and raising barriers to competitor copycats. Durable manufacturing IP improves partner confidence and supports long-term supply chain and launch planning.

Durable Clinical Efficacy SignalsStrong REO 022 results in KRAS-mutant MSS metastatic colorectal cancer—markedly longer duration of response and higher ORR versus historical SOC—provide substantive clinical differentiation. Durable efficacy in a high-need population bolsters registrational potential, commercial relevance, and partner interest over the medium term.

Regulatory Alignment Toward Registrational StudyFDA alignment on a pivotal trial design for anal carcinoma creates a clearer regulatory path, reducing execution uncertainty. A defined single-study approach for accelerated and full approval raises the probability of an efficient development timeline and strengthens the case for downstream commercialization and licensing discussions.

Bears Say

No Revenue, Sizable LossesWith no product revenue and substantial recurring net losses, Oncolytics lacks an operating cash base to fund development. This structural lack of commercialization income forces ongoing reliance on external capital, increasing long-term dilution risk and constraining reinvestment flexibility absent a successful partnership or approval event.

Persistent Negative Cash FlowSustained negative operating and free cash flow signals ongoing cash burn to support trials and R&D. Despite some improvement versus prior years, continued outflows mean the company must raise capital periodically, which can dilute shareholders and limit the firm's ability to fund parallel development programs or scale operations without external financing.

Balance-sheet Deterioration / Negative EquityEquity turning negative alongside materially lower total assets reduces financial cushioning and borrowing capacity. This structural solvency erosion elevates risk of funding shortfalls, may complicate partnership negotiations, and limits strategic optionality if development setbacks occur, making long-term execution more vulnerable.

Oncolytics Biotech News

Oncolytics secures new patent for pelareorep manufacturing

Oncolytics (ONCY) Biotech announced that the United States Patent and Trademark Office has issued a new patent protecting...

15d ago

ONCY

Oncolytics promotes John McAdory to COO

Oncolytics (ONCY) announced the appointment of Steve Glover to its board of directors and the promotion of John...

28d ago

CGON

ONCY

Oncolytics announces initial data from pelareorep combination study

Oncolytics (ONCY) announced initial data from a preclinical study evaluating pelareorep in combination with RAS inhibitor modalities in...

30d ago

ONCY

Oncolytics Biotech Secures New Pelareorep Manufacturing Patent

The latest announcement is out from Oncolytics Biotech ( ($ONCY) ). On June 16, 2026, Oncolytics Biotech Inc....

15d ago

ONCY

Oncolytics Biotech Strengthens Leadership with New COO, Director

An announcement from Oncolytics Biotech ( ($ONCY) ) is now available. On June 1, 2026, Oncolytics Biotech appointed...

29d ago

ONCY

Oncolytics Highlights Pelareorep-RAS Combo Preclinical Cancer Results

Oncolytics Biotech ( ($ONCY) ) just unveiled an announcement. On June 1, 2026, Oncolytics Biotech Inc. reported initial...

30d ago

ONCY

Oncolytics Biotech to present data at ASCO 2026 on pelareorep

Oncolytics (ONCY) Biotech announced translational data from the GOBLET and AWARE-1 trials will be presented at the 2026...

1M ago

ONCY

Oncolytics Highlights Pelareorep Immune Activation Data at ASCO

Oncolytics Biotech ( ($ONCY) ) just unveiled an update. On May 22, 2026, Oncolytics Biotech announced that translational...

1M ago

ONCY

Jason McCarthy Reiterates Buy Rating and Maintains $3 Price Target on Advancing Pelareorep Oncology Pipeline

Maxim Group analyst Jason McCarthy has reiterated their bullish stance on ONCY stock, giving a Buy rating on...

1M ago

ONCY

Oncolytics Biotech Highlights Strong Pelareorep Data in Colorectal Cancer

Oncolytics Biotech ( ($ONCY) ) just unveiled an announcement. On May 4, 2026, Oncolytics Biotech reported new data...

2M ago

ONCY

Oncolytics says in alignment with FDA following pelareorep Type C meeting

Oncolytics (ONCY) announced that a Type C meeting with the FDA has resulted in alignment on the design...

2M ago

ONCY

Oncolytics Biotech Aligns with FDA on Pelareorep Trial

Oncolytics Biotech ( ($ONCY) ) just unveiled an announcement. On April 27, 2026, Oncolytics Biotech announced it had...

2M ago

ONCY

Oncolytics Biotech: Buy Rating on Pelareorep’s Advancing Registrational Path and Oncolytic Virus Sector Tailwinds

Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Oncolytics Biotech. The associated price target...

3M ago

ONCY

Oncolytics price target lowered to $5 from $7 at Lake Street

Lake Street analyst Chad Messer lowered the firm’s price target on Oncolytics (ONCY) to $5 from $7 and...

3M ago

ONCY

ONCY FAQ

What was Oncolytics Biotech’s price range in the past 12 months?

Oncolytics Biotech lowest stock price was $0.56 and its highest was $1.51 in the past 12 months.

What is Oncolytics Biotech’s market cap?

Oncolytics Biotech’s market cap is $113.12M.

When is Oncolytics Biotech’s upcoming earnings report date?

Oncolytics Biotech’s upcoming earnings report date is Jul 31, 2026 which is in 30 days.

How were Oncolytics Biotech’s earnings last quarter?

Oncolytics Biotech released its earnings results on May 14, 2026. The company reported -$0.079 earnings per share for the quarter, missing the consensus estimate of -$0.043 by -$0.036.

Is Oncolytics Biotech overvalued?

According to Wall Street analysts Oncolytics Biotech’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Oncolytics Biotech pay dividends?

Oncolytics Biotech does not currently pay dividends.

What is Oncolytics Biotech’s EPS estimate?

Oncolytics Biotech’s EPS estimate is -0.05.

How many shares outstanding does Oncolytics Biotech have?

Oncolytics Biotech has 119,354,065 shares outstanding.

What happened to Oncolytics Biotech’s price movement after its last earnings report?

Oncolytics Biotech reported an EPS of -$0.079 in its last earnings report, missing expectations of -$0.043. Following the earnings report the stock price went down -2.523%.

Which hedge fund is a major shareholder of Oncolytics Biotech?

Currently, no hedge funds are holding shares in ONCY

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Oncolytics Biotech Stock Smart Score

Outperform

Fundamentals

Return on Equity

5214.36%

Trailing 12-Months

Asset Growth

-36.89%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Oncolytics Biotech

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.

Oncolytics Biotech (ONCY) Earnings & Revenues

Historic Earnings Reports

ONCY Stock 12 Month Forecast

Average Price Target

$6.00

▲(435.71% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","8":"$8","11":"$11","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,2,5,8,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.06,1.7476923076923077,2.4353846153846153,3.123076923076923,3.8107692307692305,4.498461538461537,5.186153846153847,5.873846153846154,6.561538461538461,7.249230769230769,7.936923076923076,8.624615384615383,9.312307692307693,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.06,1.44,1.8199999999999998,2.2,2.58,2.96,3.34,3.7199999999999998,4.1,4.4799999999999995,4.859999999999999,5.24,5.619999999999999,{"y":6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.06,1.2092307692307693,1.3584615384615386,1.5076923076923077,1.656923076923077,1.8061538461538462,1.9553846153846153,2.1046153846153848,2.253846153846154,2.403076923076923,2.5523076923076924,2.7015384615384614,2.850769230769231,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.344,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.75,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.99,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.15,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.42,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.19,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.94,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.874,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.968,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.02,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.93,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.87,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.06,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >